The main objective of the study is to assess the feasibility of using PDTO from HNSCC as tools for predicting response to treatments.
The secondary objectives are: i) to assess the feasibility of in vitro functional assays for evaluation of sensitivity to treatments (chemotherapy, radiotherapy, PARP inhibitors and immunotherapy); ii) to investigate the predictive value of PDTO for conventional chemotherapy and radiotherapy; iii) to evaluate the PARP inhibitor-mediated sensitization of radiotherapy; iv) to assess the ability of PDTO to repair DNA lesions by homologous recombination [(HRD (Homologous Recombination Deficiency)/HRI (Homologous Recombination Intermediate)/HRP (Homologous Recombination Proficiency) status); v) to identify molecular signatures for prediction of response (of PDTO and patients) to treatments.
The secondary objectives are: i) to assess the feasibility of in vitro functional assays for evaluation of sensitivity to treatments (chemotherapy, radiotherapy, PARP inhibitors and immunotherapy); ii) to investigate the predictive value of PDTO for conventional chemotherapy and radiotherapy; iii) to evaluate the PARP inhibitor-mediated sensitization of radiotherapy; iv) to assess the ability of PDTO to repair DNA lesions by homologous recombination [(HRD (Homologous Recombination Deficiency)/HRI (Homologous Recombination Intermediate)/HRP (Homologous Recombination Proficiency) status); v) to identify molecular signatures for prediction of response (of PDTO and patients) to treatments.
Free full text: Click here
